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Novel Benefits of Remote Ischemic Preconditioning Through
VEGF-dependent Protection From Resection-induced Liver
Failure in the Mouse
Patryk Kambakamba, MD, Michael Linecker, MD, Marcel Schneider, MD, Philipp Kron, MD,
Perparim Limani, MD, PhD, Christoph Tschuor, MD, PhD, Udo Ungethu¨m, Bostjan Humar, PhD,
and Pierre-Alain Clavien, MD, PhD
Objective: To investigate the impact of remote ischemic preconditioning
(RIPC) on liver regeneration after major hepatectomy.
Summary Background Data: RIPC is a strategy applied at remote sites to
mitigate ischemic injury. Unlike other preconditioning approaches, RIPC
spares target organs as it acts via systemic VEGF elevations. In the liver,
however, VEGF is an important driver of regeneration following resection.
Therefore, RIPC may have pro-regenerative effects.
Methods: RIPC was applied to C57BL/6 mice through intermittent clamping
of the femoral vessels prior to standard 68%-hepatectomy or extended 86%-
hepatectomy, with the latter causing liver failure and impaired survival. Liver
regeneration was assessed through weight gain, proliferative markers (Ki67,
pH3, mitoses), cell cycle-associated molecules, and survival. The role of the
VEGF-ID1-WNT2 signaling axis was assessed through WIF1 (a WNT
antagonist) and recombinant WNT2 injected prior to hepatectomy.
Results: RIPC did not affect regeneration after 68%-hepatectomy, but
improved liver weight gain and hepatocyte mitoses after 86%-hepatectomy.
Importantly, RIPC raised survival from 40% to 80% after 86%-hepatectomy,
indicating the promotion of functional recovery. Mechanistically, the RIPC-
induced elevations in VEGFwere accompanied by increases in the endothelial
transcription factor Id1, its target WNT2, and its hepatocellular effector b-
catenin. WIF1 injection prior to 86%-hepatectomy abrogated the RIPC
benefits, while recombinantWNT2 had pro-regenerative effects akin to RIPC.
Conclusion: RIPC improves the regenerative capacity of marginal liver rem-
nants in aVEGF-dependentway. If confirmed inpatients, RIPCmaybecome the
preconditioning strategy of choice in the setting of extended liver resections.
Keywords: hepatectomy, liver failure, remote ischemic preconditioning
(Ann Surg 2018;268:885–893)
W hile the liver has the unique capacity to fully regenerate aftermajor resection1–3 its regenerative potential is limited by the
size of the remnant left after resection.4,5 Following excessive
hepatectomies, such as necessitated through heavy tumor loads,
the marginal remnant cannot recover, leading to liver failure and
imminent death.4,6 Resection-induced liver failure, better known as
small-for-size syndrome (SFSS), is a major factor restricting the
surgical management of liver disease. Despite attempts for preven-
tive measures,7 the SFSS remains untreatable, representing an open
medical need.4,6
Since the SFSS is caused by deficient regeneration,3 strategies
with pro-regenerative potential should be prioritized. Remote ische-
mic preconditioning (RIPC), a novel approach originally designed to
mitigate surgery-associated ischemic injury,8,9 may be a candidate.
Unlike classic preconditioning approaches, RIPC spares the target
organ; in patients, brief periods of ischemia interspersed by reperfu-
sion are induced through transient mechanical obstruction of a limb.
Priming ischemia then induces peripheral signals leading to systemic
protection.8,9
In mice, we have identified VEGF as a key peripheral factor
mediating RIPC-induced protection of various organs, including the
liver, from ischemic injury.8 Although VEGF is long known to
participate in liver recovery, more recent evidence indicates VEGF
exerts crucial mitogenic effects on hepatocytes after resection.10,11
Animated through VEGF, liver sinusoidal endothelial cells (LSECs)
induce an ID1-dependent transcription program to produce HGF and
WNT2, which then act on hepatocytes to instigate and foster their
proliferation.10 Given that VEGF is central to the protective effects of
RIPC,8 the remote strategy may have pro-regenerative effects that
might be exploited for the prevention of the SFSS.
To this end, we designed a set of experiments to explore the
effects of RIPC on the regeneration of mouse liver after hepatectomy,
and to provide a mechanistic basis for a potential regenerative benefit
of RIPC. In particular, we assessed the RIPC effects in a mouse
model of resection-induced liver failure that features a regenerative
deficit, displays minimal ischemic injury, yet recapitulates all key
features of the human SFSS.3
METHODS
See Supplement for complete methods.
Experimental Design
To reveal pro-regenerative effects, RIPC and sham surgery
were performed before hepatectomies followed by the assessment of
regenerative parameters. Normal, efficient regeneration was induced
by 68%-hepatectomy, while extended 86%-hepatectomy – a vali-
dated SFSS model – is associated with a regenerative delay causing
major metabolic dysfunction (ie, persisting steatosis, hypo-albumi-
nemia, hyperbilirubinemia), liver failure, and high mortality rates.3
To explore an association with pro-regenerative VEGF sig-
naling, key components of the paracrine VEGF-ID1-HGF/WNT2-
CTNNB1 axis were analyzed for RIPC/sham-86%-hepatectomy.
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To define a role for paracrine WNT2, (i) WNT signaling was
inhibited after RIPC by WIF1 (Wnt antagonist) injection, and (ii)
RIPC was replaced by recombinant WNT2 injection.
See Supplementary Fig. S1, http://links.lww.com/SLA/B450
for an experimental overview.
Animals
All animal experiments were in accordance with Swiss federal
animal regulations and approved by the cantonal veterinary office
of Zurich (Nr. ZH234/14-25781). Male C57Bl/6 mice (Envigo,
Horst, The Netherlands) aged 10 to 12 weeks were used and kept
on a 12-hour day/night cycle with free access to food and water.
Animal Surgery
Isoflurane anesthesia and buprenorphine analgesia was fol-
lowed by RIPC. RIPC was applied by clamping the right femoral
vascular bundle just proximal to its confluence with the femoral nerve
as described8,12 and consisted of 3 cycles of 5minutes of ischemia each
followed by 5 minutes of reperfusion (Supplementary Fig. S2, http://
links.lww.com/SLA/B450). Sham RIPC consisted of 30 minutes
exposure of the femoral vascular bundle without clamping. Following
randomization of animals, standard partial 68% and extended 86%
hepatectomy were performed as previously described.3
Animal Treatment
Recombinant WIF1 (200 ng/kg, 100mL final vol., R&D Sys-
tems, Minneapolis MI, 135-WF-050) and WNT2 (200 ng/kg, 100mL
final vol., Mybiosource, San Diego CA, MBS957358) were injected
into the portal vein prior to hepatectomy.
Statistical Analysis
Five mice/group were included unless stated otherwise. Data
are presented as meanSD. Differences were assessed by Mann–
Whitney testing. Survival was assessed by Kaplan-Meier analysis
(with n ¼ 10/group, as survival is clinically the most relevant
endpoint). Significance was defined as P < 0.05. GraphPad Prism
6.0 (GraphPad Software Inc, La Jolla, CA) was used.
RESULTS
RIPC Promotes Liver Weight Gain and Survival in a
Model of Resection-induced Liver Failure (SFSS)
First, we explored the impact of murine hindlimb RIPC on
resection-induced liver regeneration. While RIPC had no significant
effects following 68%-hepatectomy (Fig. 1A, Supplementary Fig.
S3, http://links.lww.com/SLA/B450), it promoted liver weight gain
in our SFSS model (86%-hepatectomy, Fig. 1B). RIPC further
reduced liver injury (assessed through serum AST/ALT, Fig. 1C)
after 86%-hepatectomy, although overall injury levels remain low in
this model.3 No significant improvements were observed for hypo-
albuminemia and hyperbilirubinemia (Fig. 1C), however steatosis
was markedly ameliorated on histology (Fig. 1D) through RIPC.
Next, we assessed 1-week animal survival posthepatectomy, the best
measure of functional recovery in the setting of postoperative liver
FIGURE 1. The impact of RIPC on liver regeneration posthepatectomy. A, Liver weight gain (LW/BW) after RIPC or sham prior to
68%-hepatectomy. B, Liver weight gain (LW/BW) after RIPC or sham prior to 86%-hepatectomy. C, Serum AST, ALT, albumin, and
bilirubin levels after RIPC/sham and 86%-hepatectomy. D, Histology after RIPC/sham and 86%-hepatectomy. Note the steatotic
change in sham-treated liver following 86%-hepatectomy, a typical SFSS feature. E, Survival after RIPC/sham and 86%-hepatec-
tomy. N ¼ 5/group, Mann–Whitney U testing. For Kaplan–Meier analysis, n ¼ 10/group was included.
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failure.3,13,14 RIPC doubled survival rates from 40% in controls to
80% after 86%-hepatectomy (Fig. 1E). Therefore, RIPC leads to a
gain in functional liver mass when applied prior to extended
tissue loss.
The Pro-regenerative Effects of RIPC Are Associated
With the Promotion of the Hepatocellular Cell
Cycle
SFSS develops due to deficient hepatocellular cell cycle
progression.3 To determine whether RIPC promotes the cell cycle,
we assessed proliferative markers and cell cycle molecules following
86%-hepatectomy with prior RIPC/sham.
RIPC increased Ki67 counts (marking all hepatocytes in
cycle)3 without significance, did not affect total phosphohistone
3 (pH3) counts (marking all G2/M cells),
3 but significantly
elevated bold pH3 counts (marking mitotic cells)3 particularly at
48 hours posthepatectomy (Fig. 2A), the usual mitotic peak in
regenerating liver.3 These findings are consistent with an improve-
ment of the SFSS-specific cell cycle defect (ie, normal cell cycle
entry but deficient mitosis)3 through RIPC. Accordingly, RIPC did
not alter the gene expression of early phase cyclins (Ccne1, Ccnd1,
Ccna2), but promoted the expression of M-phase cyclins (Ccnb1/b2)
at 48 hours post 86%-hepatectomy, along with a marginal reduction
in Cdkn1a encoding the cell cycle inhibitor P21 (Fig. 2B).
We conclude from this 1st set of experiments that RIPC seems
to foster regeneration of SFSS grafts by facilitating the progression
through mitosis, thereby protecting from liver failure and the
associated mortality.
The Pro-regenerative RIPC Effects Are Associated
With Paracrine VEGF-ID1-WNT2-CTNNB1 Signaling
Next, we examined whether the regenerative RIPC benefits
are related to VEGF-induced, paracrine ID1-HGF/WNT2-CTNNB1
signaling (Fig. 3A).8,10
RIPC alone increased circulating VEGF levels as early as
30minutes post surgery (Fig. 3A). When combined with 86%-
hepatectomy, the RIPC-induced VEGF elevations persisted up to
6 hours after resection (Fig. 3B). In the liver, RIPC led to an increased
gene expression of the VEGF-dependent endothelial transcription
factor Id1 at 24 to 72 hours posthepatectomy, along with elevations of
the ID1-targets Hgf (significant only at 24 h) and Wnt2 (Fig. 3C). At
the protein level, hepatic HGF was elevated, albeit without reaching
significance (P ¼ 0.092, Fig. 3C). However, WNT2 protein was
significantly upregulated at 48 hours and 72 hours (Fig. 3C). To
confirm, liver tissue at 48 hours following RIPC/sham and 86%-
hepatectomy was examined by immunohistochemistry, revealing
increased WNT2 expression in RIPC- relative to sham-treated liver
(Fig. 3D). Finally, nuclear translocation of the WNT effector b-
catenin was promoted in hepatocytes through RIPC at 48 hours and
72 hours after 86%-hepatectomy (Supplementary Fig. S4, http://
links.lww.com/SLA/B450). Therefore, RIPC promotes peripheral
VEGF, the sinusoidal ID1-WNT2 axis, and nuclear b-catenin
FIGURE 2. Assessment of proliferative parameters after RIPC and 86%-hepatectomy. A, Immunohistochemistry for hepatic Ki67
(marking all cells in cycle), total pH3 (markingG2 andM cells), bold pH3 (markingM cells), and corresponding quantifications to the
right. Note the significant increases inmitotic cells in liver of RIPC-treatedmice. B, Hepatic expression of genes encoding cyclins D1,
E1, A2, the cell cycle inhibitor p21, and the mitotic cyclins B1/2 at 48h after 86%-hepatectomy in mice pretreated with RIPC or
sham. Note the cyclin B upregulation through RIPC. N ¼ 5/group, Mann–Whitney U testing.
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translocation in hepatocytes. These findings suggest that the pro-
regenerative effects of RIPC rely on paracrine VEGF-ID1-WNT2-
CTNNB1 signaling between LSECs and hepatocytes.
The Pro-regenerative and Pro-proliferative RIPC
Effects Are Dependent on WNT2
If RIPC acts through WNT2, WNT2 inhibition should abro-
gate the RIPC effects, while exogenous WNT2 should mimic
RIPC effects.
For WNT2 inhibition, recombinant WIF1 (Wnt inhibitory
factor) was injected after RIPC/sham before 86%-hepatectomy
(Fig. 4A). Outcomes were compared to RIPC-86%-hepatectomy-
treated mice injected with saline. WIF1 treatment inhibited liver
weight gain at both 48 hours and 72 hours after RIPC-86%-hepatec-
tomy (Fig. 4B). When recombinant WNT2 was injected before 86%-
hepatectomy in the absence of RIPC (Fig. 4A), liver weight was
increased akin to RIPC mice relative to saline-injected controls at
72 hours (P ¼ 0.017, Fig. 4B).
Relative to sham-treated animals, WIF1 treatment of RIPC-
86%-hepatectomy mice did not significantly affect Ki67, total pH3,
and bold pH3 counts (Fig. 5A), indicating RIPC loses its proliferative
effects if WNT2 is inhibited. In contrast, pretreatment of hepatecto-
mized mice with recombinant WNT2 marginally increased Ki67
counts but significantly elevated bold pH3 counts (Fig. 5A) akin to
FIGURE 3. Serum VEGF levels and associated hepatic downstream signaling after RIPC and 86%-hepatectomy. A, The proposed
signaling cascade induced by RIPC in hepatectomized mice: a key mechanism underlying the known RIPC effects is the release of
circulating VEGF from peripheral endothelial cells. VEGF may then stimulate LSECs to induce via the transcription factor ID1 the
production of paracrine HGF andWNT2, with the latter ligand causing nuclear translocation of b-catenin in hepatocytes to promote
their proliferation. B, Serum VEGF levels after RIPC or sham without hepatectomy, and after RIPC/sham and subsequent 86%-
hepatectomy. C, Hepatic gene expression levels of Id1, Hgf andWnt2, and hepatic protein levels of HGF andWNT2 after RIPC/sham
and 86%-hepatectomy. D, Representative immunohistochemical stain for hepatic WNT2 after RIPC/sham and 86%-hepatectomy.
N ¼ 5/group, Mann-Whitney U testing.
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the effects of RIPC (Fig. 2A), confirming that at least some of the
pro-proliferative RIPC action is mediated through the ligand. These
changes were accompanied by an upregulation of mitotic cyclin
genes (Fig. 5B), qualitatively mirroring the RIPC effects on cell cycle
molecules (Fig. 2B). Furthermore, WNT2 increased the M-phase
promoter Foxm1 and reduced P21 gene expression (Fig. 5B). Again,
the impact of WNT2 on B cyclins was less pronounced than that of
RIPC, consistent with other contributing molecules or a lesser
activity of the recombinant protein. Nonetheless, these findings
associate WNT2 upregulation with the promotion of hepatocyte
mitosis leading to an improved liver weight gain after 86%-hepatec-
tomy.
Finally, WNT2 treatment, but not RIPC-WIF1 treatment, led
to increased nuclear translocation of hepatocellular b-catenin fol-
lowing 86%-hepatectomy (Fig. 5C). No significant changes were
observed for albumin and bilirubin (data not shown) both of which
were not affected by RIPC. The persisting steatosis characteristic of
the SFSS was present after WIF1 injection, but was markedly
reduced through WNT2 treatment at 48 hours after 86%-hepatec-
tomy (Fig. 5C). Therefore, the pro-regenerative RIPC effects are
dependent on WNT2 signaling, while the application of exogenous
WNT2 can mimic most benefits of RIPC in settings of SFSS
hepatectomy.
Altogether, our experiments demonstrate that RIPC can foster
the regeneration of marginal liver grafts via paracrine VEGF-ID1-
WNT2 signaling from LSECs, which stimulates hepatocellular
mitosis through nuclear b-catenin translocation.
DISCUSSION
RIPC is a preconditioning approach unique with regards to its
application and its systemic effects. Local ischemia inflicted through
RIPC at a limb is sufficient to spread systemic protection from
subsequent ischemic stress to various organs. The RIPC effects may
extend beyond ischemic protection; in rodent models, RIPC is able to
mitigate pancreatitis and hepatic acetaminophen toxicity.8 Here, we
report a novel benefit of RIPC in mice, which is the promotion of
regeneration of small liver remnants after major hepatectomy.
The SFSS is one of the most feared complications after major
hepatectomy, leading to deterioration of liver function and even death
of the patient. Despite numerous advances in liver surgery, reliable
strategies to prevent the SFSS in the clinic are not available thus far.
FIGURE 4. The inhibition of RIPC effects through WIF1 and the stimulation of RIPC effects through recombinant WNT2. A,
Experimental setup for WIF1 administration after RIPC prior to 86%-hepatectomy, andWNT2 administration instead of RIPC before
hepatectomy. Standard RIPC plus 86%-hepatectomy served as reference. B, Liver weight gain (LW/BW) at 48h and 72h after sham
or RIPC plusWIF1 plus 86%-hepatectomy. C, Liver weight gain at 48h and 72h after PBS injection (control) plus 86%-hepatectomy,
and after WNT2 injection plus 86%-hepatectomy. N ¼ 5/group, Mann–Whitney U testing.
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FIGURE 5. Assessment of proliferative parameters following RIPC inhibition through WIF1 and following WNT2 administration
instead of RIPC. A, Hepatic Ki67, total pH3 and bold pH3 counts after RIPC or sham plus WIF1 and subsequent 86%-hepatectomy
(left panels). Similarly, counts are shown (right panels) for mice subjected to 86%-hepatectomy with concomitant PBS or WNT2
injection. B, Hepatic expression of genes encoding cyclins D1, E1, B1, and B2, the cell cycle promoter FOXM1, and the cell cycle
inhibitor P21. Left panels show data for mice subjected to RIPC/sham, WIF1 injection and 86%-hepatectomy, while right panels
show data for mice subjected to PBS/WNT2 injection followed by 86%-hepatectomy. N ¼ 5/group, Mann–Whitney U testing. C,
Comparison of nuclear b-catenin expression between liver samples frommicewhere RIPC effects have been bluntedwithWIF1 prior
to 86%-hepatectomy, and frommice that have been stimulated with WNT2 prior to 86%-hepatectomy. Note the elevated nuclear
staining in WNT2-exposed liver. The histology to the right indicates persisting steatosis in WIF1 – but not WNT2-treated animals.
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In a randomized trial, we have observed that pentoxifylline (PTX, a
promoter of the pro-regenerative interleukin-6 pathway) was able to
promote the regeneration of small remnants after major hepatecto-
mies. Unfortunately, PTX could not be further considered for clinical
application due to unacceptable toxicities associated with this com-
pound.7 While liver regeneration is influenced by various patient
related (eg, age, underlying liver disease) and surgical (eg, blood loss,
ischemia) parameters, we investigated a reproducible mouse model
of SFSS that excludes the latter irregularities.3 Akin to humans, our
model features delayed regeneration, metabolic deficiencies (hypo-
albuminemia, hyperbilirubinemia, persisting steatosis), and impaired
survival.3 Therefore, this model provides an ideal, standardized
setting for the study of RIPC effects on marginal liver remnants.
In our SFSS model, RIPC was efficient in enhancing hepatocellular
mitosis and liver weight gain, while ameliorating steatosis. Although
hypoalbuminemia and hyperbilirubinemia remained unaffected,
RIPC prior to SFSS hepatectomy enabled doubling of survival,
indicating it does promote vital metabolic tasks of marginal liver
remnants. Survival remains the most relevant endpoint, particularly
as the SFSS is the commonest cause of death due to liver surgery.5
VEGF-dependent signaling seems to be central for the RIPC
benefits in both ischemia8,12 and the SFSS. VEGF-induced angio-
crine signals from LSECs have been shown to be pivotal to the
regeneration of the parenchyma.10 If the VEGF receptor, or its
downstreammediator ID1, are deleted in LSECs, hepatocytes display
a severe proliferative defect, and liver regeneration is strongly
compromised after hepatectomy. This regenerative defect can be
corrected by the exogenous provision of HGF and WNT2, the 2
paracrine ligands that are induced by ID1 and act as hepatocyte
mitogens.10 In analogy, we show that RIPC upregulates the endo-
thelial VEGF-ID1 axis, its target WNT2, and the hepatocellular
WNT effector b-catenin, a key driver of parenchymal proliferation
after resection.15
Moreover, via modulation of the paracrine mediator WNT2,
we demonstrate the importance of this intercellular pathway for
RIPC. Altogether, we provide the first evidence that RIPC can exert
pro-regenerative effects via paracrine signaling through the
VEGF!LD1!WNT2!CTNNB1 pathway.
RIPC displayed little effect when applied before standard
68%-hepatectomy. Therefore, RIPC appears not to be able to
enhance an already efficient regenerative response as induced in
mice by standard hepatectomy. In contrast, extended (86%) hepatec-
tomy in mouse leads to a P21-dependent arrest of the hepatocellular
cycle at the M-phase,3 a defect that seems to be specifically targeted
by RIPC (ie, elevation of mitotic cyclins, reduction in P21, promotion
of mitotic pH3 counts). Notably, preliminary findings from our group
suggest that WNT2-CTNNB1 signaling is downregulated after 86%-
relative to 68%-hepatectomy (Dr Kachaylo, pers.comm.). Therefore,
compromisedWNT signaling can conceivably explain the efficacy of
RIPC specifically in the setting of experimental SFSS.
Besides WNT signaling, RIPC might improve SFSS resec-
tions by promoting a healthy LSEC phenotype. Both RIPC and
VEGF can maintain open LSEC fenestration,11,12 which is needed
for a normal regenerative capacity16 and reduces exaggerated portal
pressure,17 a proposed cause of the SFSS. Intriguingly, exogenous
VEGF can improve liver regeneration also in a steatotic or cirrhotic
background.18–20 These findings imply that (i) RIPC may be substi-
tuted through VEGF delivery to achieve more targeted benefits, and
that (ii) RIPC/VEGF might be beneficial also in a background of
liver disease.
RIPC is a recent preconditioning method, and its clinical
efficacy is being evaluated.21,22 We have initiated a clinical trial
assessing the impact of RIPC on postoperative complications asso-
ciated with major surgical procedures including hepatectomies
(NCT02375269). Meanwhile, experimental data can give hints to
estimate the advantages that may be expected fromRIPC. Comparing
RIPC with intermittent clamping (IC, the gold standard protective
strategy) and direct ischemic preconditioning (IPC), we found RIPC
superior in the protection of old mouse liver from ischemic injury.12
The superior efficacy was associated with enhanced VEGF induction
compared with IC, while IPC did not induce detectable VEGF and
failed to provide benefit in the aged liver. Notably, IC may promote
rat liver regeneration, however only when applied to the lobes to be
resected – otherwise deterioration sets in.23 In contrast, IPC has been
reported to worsen rat regeneration.24 Therefore, the available evi-
dence favors RIPC with regards to both its protective and its pro-
regenerative potential, however bound to a background of healthy
liver. Whether RIPC will perform also in diseased liver will require
additional study. Ultimately, a well-designed trial comparing the
different preconditioning approaches in patients undergoing
extended resection will be needed to define the clinical utility of
RIPC. Importantly, future trials should include all relevant endpoints
to assess the efficacy of RIPC against the SFSS. Measures for the
prevention of the currently untreatable SFSS represent one of the
main challenges in liver surgery, and the ease of RIPC application
strongly argues for its clinical feasibility.
In conclusion, we report that RIPC is able to promote the
regeneration of marginal liver remnants leading to an improved
survival after extended hepatectomy in the mouse. This novel feature
is associated with the systemic elevation of peripheral VEGF elicited
through RIPC, and relies on the paracrine stimulation of hepatocyte
mitosis via VEGF-ID1-WNT2 signaling from LSECs. The pro-
regenerative potential adds to the already described benefits of RIPC,
including the non-invasive nature, the sparing of the target organ, the
protection beyond ischemic insults, and the efficacy in aged liver. If
confirmed in the clinic, RIPC may become the preconditioning
method of choice in settings of extended hepatectomies ongoing
with an elevated SFSS risk.
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DISCUSSANTS
Jacques Pirenne (Leuven, Belgium):
RIPC has been studied more as a strategy against ischemia
than to promote regeneration. Distinct mechanisms, among which is
the induction of HIF, have been involved in the protection against
ischemia. First, is there an overlap between the pro-regenerative and
the anti-ischemic effects of RIPC, or are they different?
Have you (or others) used the same RIPC protocol to test
resistance to ischemia (liver, kidneys, etc.)?
Second, the SFSS syndrome is caused by insufficient hepato-
cyte regeneration. It is also caused by an increased portal pressure
and endothelial shear stress. In the clinics, maneuvers proven to
reduce portal pressure – that is portal shunting – can prevent SFSS.
Did RIPC act on portal pressure, too? Is there a possibility that RIPC
promoted endothelial protective factors?
Third, the difficulty in translating RIPC from controlled
rodent experiments to the clinic is the multifactorial nature of the
human setting, and the uncertainty on the length and severity of the
ischemia that is required. In this study, you hypothesize that VGEF is
the afferent effector. So, why did you not use VGEF directly instead
of the relatively crude maneuver of RIPC (arm or limb ischemia)?
Have you tried to infuse VGEF? It would help to prove your
hypothesis that VGEF is indeed the primum movens of the pro-
regenerative mechanisms of RIPC. It would also make clinical
application easier.
Finally, many livers are discarded for transplantation because
of steatosis. I was interested by the reduction of steatosis, which you
observed in your treated rodents. What could be the mechanism? Is
VEGF involved? It might be worth exploring the effect of RIPC on
steatotic livers.
Response From Patryk Kambakamba (Zurich,
Switzerland):
Thank you for evaluating our manuscript and for your ques-
tions. I will go through each question point by point.
First, regarding the mechanistic overlap, RIPC induces circu-
lating VEGF elevations, which mediate both its protective and pro-
regenerative effects. Downstream of VEGF, however, the protective
RIPC effects are associated with IL-10 and MMP8 elevations in
various target organs, which we have previously shown using the
same RIPC protocol.1 On the other hand, the pro-regenerative RIPC
effects depend on VEGF signaling in sinusoidal endothelial cells,
which then produce WNT2 to stimulate pro-regenerative WNT
signaling in hepatocytes in a paracrine fashion.
Second, elevated portal pressure is often discussed as one of
the factors causing the small-for-size syndrome. We did not assess
the portal pressure. However, both RIPC2 and VEGF3 are known to
maintain open sinusoidal fenestration, which in turn, is thought to be
a prerequisite for normal regeneration4 and can lower exaggerated
portal pressure.5 It is, thus, also likely that RIPC will have beneficial
effects on portal pressure.
Third, as for VEGF injections, I believe that the advantage of
RIPC is its ease of application, the lack of significant side effects, and
the fact that it can be done anywhere. Recombinant VEGF injections
will be more costly; however, they might be a better choice for
patients, in which RIPC has not achieved sufficient effect (ie, due to
insufficient VEGF elevations). Indeed, others have shown that VEGF
injections promote liver regeneration.6
Finally, given that fat is a primary energy source for the
regenerating liver,7 we posit that the reductions in regeneration-
associated steatosis are a simple consequence of better regeneration
that needs more fat. Nevertheless, it would be worthwhile to explore
RIPC in steatotic livers, as others have shown improved regeneration
of fatty liver following VEGF injection.6
Norbert Senninger (Mu¨nster, Germany):
Dr. Kambakamba, thank you very much. I think that your
group should be congratulated for bringing new aspects into clinical
application. You showed us the proof of principle that the VEGF-
induced regeneration of the liver might be helpful. You showed us
physiological parameters. I do have a central concern, however,
about the effect of the VEGF on the tumor cells. You know about
minimal residual disease. Every manipulation of a tumor-bearing
liver causes circulating tumor cells, which will be lodged somewhere.
While they will eventually be destroyed, they are still present. If
you’re adding something that makes cells more viable, you’re then
also perhaps making tumor cells more viable in the process. Did you
investigate the effects of VEGF on the tumor cells?
Response From Patryk Kambakamba (Zurich,
Switzerland):
Thank you for this important question. I am not aware of any
study associating RIPC with an increased risk of recurrence follow-
ing liver surgery. I think that RIPC induces only modest and transient
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VEGF elevations, which are sufficient to aid the regenerative
response. We would need to investigate whether such elevations
will have any impact on tumor cells. However, VEGF is usually
associated with hypoxic tumors, and not with circulating, individual
tumor cells, such as those released through surgery. Therefore, I
believe the associated oncological risks will be acceptable.
Christiane Bruns (Cologne, Germany):
Thank you very much for the nice presentation. My first
question is concerning the methods of the experimental setting.
Using the extended partial hepatectomy model, you evaluated a
small-for-size syndrome as well as an increase of the remaining
liver lobe in relation to the bodyweight of the animals. Could you
comment on the bodyweight of the animals that received an extended
hepatectomy? I am curious whether the bodyweight of these animals
was much less than the control group.
Second, you postulate that the recruited VEGF based on the
remote ischemic preconditioning in the limb of the animals is the
reason for the effects in the remaining liver lobe after extended partial
hepatectomy, which is an endocrine effect. In addition, extended
partial hepatectomy causes substantial VEGF upregulation in hep-
atocytes of the remaining liver lobe. Could you comment on this?
Finally, you measured a substantial activation of WNT sig-
naling. The translocation of cellularWNT into the nucleous triggers a
lot of signaling cascades, which promote metastases. I am wondering
how you discussed this regarding the transfer of remote ischemic
preconditioning into clinical trials, since almost all patients eligible
for this concept suffer from primary or secondary liver tumors.
Response From Patryk Kambakamba (Zurich,
Switzerland):
Thank you for these comments.
Concerning your first question, we have to keep in mind that
both the RIPC and control groups were subjected to the same
extended hepatectomy. Accordingly, remnant-to-bodyweight ratio
was similar at hepatectomy for both groups.
Regarding your second question, RIPC elevates both systemic
and hepatic VEGF, but I did not show the results of the latter. The
main wave of VEGF from hepatocytes, however, occurs at a later
stage and serves to promote the regeneration of sinusoids.8
Finally, WNT-b-catenin signaling is well known for its tumor-
igenic effects. After RIPC, we get a transient and modest nuclear b-
catenin accumulation, which promotes regeneration after an
extended hepatectomy, but not after a standard one, pointing to a
limited effect of RIPC on b-catenin activity. In contrast, tumors need
chronic b-catenin over-activation to flourish. Therefore, I believe
that the transient b-catenin activation through RIPC will have little
impact on residual tumor cells.
Thomas van Gulik (Amsterdam, The Netherlands):
I enjoyed your presentation. Congratulations on these very
nicely performed experiments. I would also like to elaborate on the
role of VEGF a little further. Obviously, when you extrapolate the
whole concept of VEGF to the use of liver augmenting techniques to
induce liver regeneration, we know that VEGF plays a crucial role.
This is mediated by a mechanism of increased perfusion and
concomitant angiogenesis, which is also the reason why tumor
growth is stimulated, as a result of neoangiogenesis. So, my question
is as follows: why didn’t you simply measure the levels of VEGF in
your model, and why didn’t you look at neoangiogenesis from a
histological perspective because this is what happens when you study
the effects of VEGF?
Response From Patryk Kambakamba (Zurich,
Switzerland):
Thank you for this question. Certainly, VEGF will have an
effect on angiogenesis, but the VEGF-ID1-WNT2 axis has direct
mitogenic effects on hepatocytes after resection.9 Following an
extended hepatectomy, we think that angiogenesis is merely delayed8
and not a cause of liver failure. This is why we did not investigate
angiogenic activities. However, we assume that the pro-regenerative,
hepatocellular effects of RIPC will also normalize angiogenic activ-
ities, as successful hepatocyte mitosis is a trigger for the subsequent
angiogenic phase after hepatectomy.8
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